Article: Alder Biopharmaceuticals Announces Expanded Collaboration With Schering-Plough.

Therapeutic Monoclonal Antibodies Generated From Antibody Identification & Production Technologies Selected as Lead Candidates

BOTHELL, Wash. -- Alder Biopharmaceuticals, Inc., an emerging antibody therapeutics company, today announced the expansion of its collaborative alliance with leading pharmaceutical company Schering-Plough Corporation (NYSE: SGP). The collaboration continues to be successful in identifying numerous high quality therapeutic monoclonal antibody lead candidates.

Candidates with potential applications to Central Nervous System (CNS) disorders are being identified through the application of Alder's innovative high throughput antibody ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!